See more : Avant Technologies Inc. (AVAI) Income Statement Analysis – Financial Results
Complete financial analysis of ProSomnus, Inc. (OSAPQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProSomnus, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Beghelli S.p.A. (BE.MI) Income Statement Analysis – Financial Results
- Mochida Pharmaceutical Co., Ltd. (4534.T) Income Statement Analysis – Financial Results
- Samvardhana Motherson International Limited (MOTHERSON.BO) Income Statement Analysis – Financial Results
- Novem Group S.A. (NVM.DE) Income Statement Analysis – Financial Results
- Numis Corporation Plc (NUM.L) Income Statement Analysis – Financial Results
ProSomnus, Inc. (OSAPQ)
About ProSomnus, Inc.
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California. On May 7, 2024, ProSomnus, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 27.65M | 19.39M | 14.07M | 8.29M |
| Cost of Revenue | 13.64M | 9.13M | 6.76M | 4.17M |
| Gross Profit | 14.01M | 10.27M | 7.31M | 4.12M |
| Gross Profit Ratio | 50.67% | 52.94% | 51.94% | 49.73% |
| Research & Development | 4.80M | 2.98M | 1.89M | 1.47M |
| General & Administrative | 15.23M | 9.90M | 4.47M | 3.29M |
| Selling & Marketing | 13.09M | 8.87M | 5.78M | 3.52M |
| SG&A | 28.32M | 18.76M | 10.24M | 6.81M |
| Other Expenses | -770.00K | 551.00K | 0.00 | 10.00K |
| Operating Expenses | 33.12M | 21.74M | 12.13M | 8.28M |
| Cost & Expenses | 46.76M | 30.87M | 18.90M | 12.44M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.38M | 6.12M | 3.25M | 2.01M |
| Depreciation & Amortization | 978.00K | 424.00K | 827.57K | 573.27K |
| EBITDA | -21.37M | -10.50M | -3.99M | -3.57M |
| EBITDA Ratio | -77.29% | -54.14% | -28.38% | -43.14% |
| Operating Income | -19.11M | -11.48M | -4.82M | -4.15M |
| Operating Income Ratio | -69.09% | -59.17% | -34.26% | -50.06% |
| Total Other Income/Expenses | -4.99M | 4.33M | -1.15M | -2.01M |
| Income Before Tax | -24.10M | -7.15M | -5.98M | -6.16M |
| Income Before Tax Ratio | -87.14% | -36.84% | -42.47% | -74.29% |
| Income Tax Expense | 4.61M | 6.67M | 3.25M | 17.67K |
| Net Income | -24.10M | -7.15M | -5.98M | -6.17M |
| Net Income Ratio | -87.14% | -36.84% | -42.47% | -74.50% |
| EPS | -1.49 | -0.45 | -0.37 | -0.38 |
| EPS Diluted | -1.49 | -0.45 | -0.37 | -0.38 |
| Weighted Avg Shares Out | 16.18M | 16.04M | 16.05M | 16.05M |
| Weighted Avg Shares Out (Dil) | 16.18M | 16.04M | 16.05M | 16.05M |
Source: https://incomestatements.info
Category: Stock Reports